Indigo Aspiration System is a minimally-invasive device used to remove emboli and thrombi from vessels of the peripheral arterial and venous systems, and for treatment of pulmonary embolism, and enables the restoration of blood flow
US-based Penumbra has teamed up with Japanese medical device manufacturer Asahi Intecc to roll out its Indigo Aspiration System in Japan, after receiving regulatory approval.
Indigo Aspiration System is used to remove emboli and thrombi from vessels of the peripheral arterial and venous systems, and for the treatment of pulmonary embolism.
Also, the minimally-invasive device enables the restoration of blood flow in cases such as acute limb ischemia and venous thrombus.
It leverages the Penumbra ENGINE aspiration source, which delivers an almost pure, continuous vacuum to help catheters remove thrombus in vessels of varied sizes.
The US-based medical device maker said that the collaboration will combine its latest innovations with Asahi’s leadership and expertise in the Japanese medical device market.
Penumbra president and CEO Adam Elsesser said: “We can provide physicians in Japan with technology that has been proven highly effective, helping patients return home quickly and in good health.
“This furthers our commitment to advance novel technologies to address unmet needs and improve patient care worldwide.”
Penumbra said that its new-generation Indigo system will combine hypotube-based aspiration catheters, together with Lightning Intelligent Aspiration.
Lightning Intelligent Aspiration is a unique computer-aided clot detection technology that differentiates between clot and blood, to reduce blood loss and the need for clot-dissolving drugs.
The company’s long-time partner Medico’s Hirata will continue to distribute its neurovascular thrombectomy and neurovascular and peripheral embolisation devices.
The devices include the latest RED reperfusion catheters to help navigate the complex anatomy of the brain and deliver effective aspiration for the removal of blood clots.
Asahi Intecc president and CEO Masahiko Miyata said: “Our companies share a similar mission to help expand the available treatment options for serious conditions that impact an increasing number of people in Japan.
“We believe that, together, we are able to provide physicians with the latest innovations that best meet their patients’ needs and help advance patient care.”